siRNA, mRNA, pick-your-favorite-RNA, CRISPR, ADCs, PROTACs, molecular glues, precision-meds, CAR-T, epigenetic and allosteric modulators, AI/ML-everything, tissue-selective nanoparticles, AAV delivery systems, etc. These are all novel drug or delivery modalities with potential to significantly impact patients’ lives and global health (some have already succeeded), but with various degrees of “validation,” whether preclinically, clinically, or commercially. Join this panel for an exciting conversation with a panel of biotech entrepreneurs, business development and R&D industry leaders as they explore topics around platform build, modality value drivers, what does modality “validation” mean to pharma, how do patients in need of innovative medicines factor in, what’s partnerable and what’s not, what is the desired data package to catalyze partnering discussions, macro considerations that impact deal terms and process, and when should pharma take a leap-of-faith decision to partner early/pre-validation vs. wait for key in vivo data.